The global Autoinjectors Market is set to grow from USD 1.40 billion in 2024 to a projected value of USD 3.02 billion by 2030, at a significant CAGR of 13.6%. Similarly, the autoinjector finished formulations market is forecasted to rise from USD 67.30 billion in 2024 to USD 134.27 billion by 2030, growing at a CAGR of 12.2%. Key factors contributing to this growth include favorable reimbursement policies and an increasing number of regulatory approvals for autoinjectors.
Download an Illustrative overview:
The market report covers 527 data tables, 75 figures, and spans 382 pages, offering detailed insights into the autoinjectors market by usage (disposable, reusable), technology (manual, automatic), therapy area, and route of administration.
Key Market Insights:
Rheumatoid Arthritis Leading the Market
The autoinjectors market is segmented by therapy into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, obesity, and others. In 2023, rheumatoid arthritis accounted for the largest market share. The growing prevalence of rheumatoid arthritis and the availability of autoinjectors for its treatment are key drivers. The obesity segment is anticipated to grow at the highest CAGR during the forecast period, spurred by the launch of novel products and increasing adoption of autoinjectors for weight management. Notably, as of August 2024, Australia's Therapeutic Goods Administration (TGA) approved the availability of Wegovy (semaglutide) for weight management.
Reusable Autoinjectors Set to Experience Significant Growth
The market is also categorized based on usage into reusable and disposable autoinjectors. While disposable autoinjectors held the fastest-growing share in 2023 due to ease of use, demand for self-administration, and lower risk of cross-contamination, the reusable autoinjectors segment is expected to grow at a significant CAGR from 2024 to 2030. Innovations in reusable autoinjectors, including ergonomic designs, digital interfaces, and enhanced safety features, are driving increased adoption, particularly in developing countries.
Europe: A Key Regional Market
Europe is the second-largest market for autoinjectors globally, benefitting from favorable reimbursement and regulatory policies. The rising prevalence of chronic diseases and the growing use of autoinjectors among patients in this region are contributing to market growth. Key market players such as SHL Medical and Ypsomed are also instrumental in driving this growth.
Leading Market Players
Key players in the autoinjector devices market include SHL Medical AG (Switzerland), Ypsomed AG (Switzerland), Becton, Dickinson and Company (BD) (US), Recipharm AB (Sweden), and West Pharmaceutical Services, Inc. (US). In the finished formulations segment, major companies include Abbvie Inc. (US), Eli Lilly and Company (US), Amgen Inc. (US), Novo Nordisk A/S (Denmark), Johnson & Johnson Services Inc. (US), and Sanofi (France).
Content Source:
https://www.marketsandmarkets.com/PressReleases/autoinjector.asp
https://www.marketsandmarkets.com/ResearchInsight/autoinjector-market.asp
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Comments
0 comment